Measurement of circulating 25-hydroxyvitamin D: A historical review by Delvin, Edgar et al.
                             Elsevier Editorial System(tm) for Practical Laboratory Medicine 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Measurement of circulating 25-hydroxyvitamin D: A historical review  
 
Article Type: Review Article 
 





mass spectrometry,  
immunoassays 
 
Corresponding Author: Dr. Edgard E. Delvin, PhD 
 
Corresponding Author's Institution: Montreal Children's Hospital, McGill University 
 
First Author: Edgard E. Delvin, PhD 
 
Order of Authors: Edgard E. Delvin, PhD; Caroline Le Goff, PhD; Étienne Cavalier, PhD; Jean-Claude 
Souberbielle, MD 
 
Abstract: The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over 
the last years has led reagent manufacturers to market different automated and semi-automated 
methods, that being unfortunately not fully harmonized, yield different results. Liquid chromatography 
coupled to tandem mass spectrometry (LC/MS2) has more recently been introduced. This approach 
allows the distinction between the two forms of 25-hydroxyvitamin D and to measure other 
metabolites. This approach also requires harmonization to curtail the differences between the different 
analytical methods. To meet this requirement, the American National Institutes of Health (NIH), the 
CDC (Centre for Disease Control and Prevention) in Atlanta, the NIST (National Institute of Standards 
and Technology) and the vitamin D Reference laboratory of Ghent University have pooled their 
expertise to develop a standardization program. 
This article reviews the main elements and the difficulties of the automated and semi-automated 
methods for 25-hydroxyvitamin D, from sample preparation to the analytical phase, as well as those 
related to mass spectrometry. It also addresses the issues related to the clinical decision thresholds 





















Service de Chimie Clinique, CHU de Liège, Belgique;
 2
Service des explorations fonctionnelles 
Hôpital Necker-Enfants malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 
3






Correspondence: Edgard Delvin, Centre de recherche, CHU Ste-Justine, 3175 Côte Ste-
Catherine, Montréal, Québec Canada H3T 1C5. Tel: (450) 681-1715. 
 Email: delvine@sympatico.ca 
 
 
Keywords: Vitamin D, 25-hydroxycholecalciferol, 25-hydroxyergocalciferol, 25OHD, HPLC, 
mass spectrometry, immunoassays. 
  
Manuscript
Click here to view linked References
Abstract 
The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over the 
last years has led reagent manufacturers to market different automated and semi-automated 
methods, that being unfortunately not fully harmonized, yield different results. Liquid 
chromatography coupled to tandem mass spectrometry (LC/MS
2
) has more recently been 
introduced. This approach allows the distinction between the two forms of 25-hydroxyvitamin D 
and to measure other metabolites. This approach also requires harmonization to curtail the 
differences between the different analytical methods. To meet this requirement, the American 
National Institutes of Health (NIH), the CDC (Centre for Disease Control and Prevention) in 
Atlanta, the NIST (National Institute of Standards and Technology) and the vitamin D Reference 
laboratory of Ghent University have pooled their expertise to develop a standardization program. 
This article reviews the main elements and the difficulties of the automated and semi-automated 
methods for 25-hydroxyvitamin D, from sample preparation to the analytical phase, as well as 
those related to mass spectrometry. It also addresses the issues related to the clinical decision 
thresholds and the possibility of measurements in different biological liquids. 
  
Introduction 
The role of cholecalciferol or vitamin D3 in growth and bone metabolism is well established [1]. 
Its effects in the prevention and treatment of diseases as varied as diabetes, multiple sclerosis and 
cancer have also been reported, but are still matter of debate [2-6]. Both the Institute of Medicine 
(IoM) [7] and the Agency for Healthcare Research and Quality (AHRQ) [8] have published 
extensive documents dampening the optimism aroused by these reports. The AHRQ report [8] 
makes the case that studies (observational, randomised controlled interventions) and systematic 
reviews or meta-analyses based on those, involved different types of assays that, except for the 
most recently published, did not use appropriate reference material. It also shows, as a series of 
bubble plots, that there was an important variation in responses to vitamin D supplementation 
(Figure 1). This apparent variation is multifactorial. The individual response to sun exposure and 
the formulation of the vitamin D supplement are parts of the equation. However, inter-laboratory 
variations also contribute to this observation as they hinder comparison between results. Indeed, 
the inter-laboratory differences between the mean serum 25OHD values, that reached almost 
32%, according to a DEQAS survey in 1994, could have, in those years, possibly lead to 
misclassification of patients in terms of vitamin D nutritional status, despite the fact that their 
ranking might have been similar. Since then, the standardisation process has improved, and in 
2009, the inter-laboratory imprecision had dramatically decreased [9], and thus if similar 
experiments were conducted today, the dose-response relationship might be tighter. In any case, 
these limitations restrain the conclusions of past epidemiological studies on the circulating 
25OHD concentrations required for optimal health status. 
As it has often been mentioned, the number requests for the measurement of circulating 25-
hydroxyvitamin D (25OHD), the accepted biomarker for the vitamin D nutritional status [10,11], 
has constantly increased over the last 3 decades, imposing structural and financial burdens on 
laboratory facilities and public funding. The Ontario Health Technology Advisory Committee 
(OHTAC) has reported that, the volume of laboratory vitamin D tests had increased from 
approximately 30,000 in 2004 to over 730,000 in 2009 [12]. Similar observations were made 
worldwide. This increased request load has lead most of the clinical laboratories to abandon 
manual binding-protein assays and radio-immunological assays (RIAs), the methods mostly 
utilised clinical laboratories in the 1980s and early 1990s, in favour of automated competitive 
binding-protein assays (CBPA), enzyme-linked immunoassays (ELISAs) or chemiluminescent 
immunoassays (CLIA). Techniques based on high-performance liquid chromatography (HPLC), 
coupled or not to simple or tandem mass spectrometry, while more exact, are still the privilege of 
specialised and research laboratories.  
The variety of circulating vitamin D metabolites and the complex nature of the matrix makes the 
measurement of 25OHD difficult, despite the technological advances. Many important issues 
have still to be resolved to obtain an accurate measure of serum 25OHD concentration. Each 
phase of the process will be reviewed in order to provide clinical laboratories with information on 
the difficulties they have to face. 
The sample preparation phase 
In order to understand the problems related to the recovery of 25OHD during the extraction 
procedures, one must have some knowledge of the physiological processes involved in its 
transport. Due to their lipophilicity, vitamins D3 and D2, as well as their respective hydroxylated 
metabolites (ligands), must be transported by amphoteric carriers. Although vitamin D binding-
protein (DBP) is their predominant transporter, albumin and lipoproteins are also important 
components. Whereas vitamin D synthesised in the skin is preferentially transported by DBP to 
be hydroxylated in the liver, lymphatic chylomicrons and lipoproteins mediate its transport and 
hepatic uptake [13-16].  
Each ligand-vitamin D-carrier complex possesses its own affinity constant. For example 25OHD 
binds DBP with high affinity (Ka = 5X10
−8
 M), whereas 1,25(OH)2D, the hormonal form of 
vitamin D, exhibits a lower affinity (Ka=4X10
−7
 M) [17,18]. In both cases the carrier being in 
large excess (<5%) of the DBP sites are occupied), the free concentrations of the metabolites are 
thus extremely low. The other transporters have similar kinetics at however different orders of 
magnitude. It becomes apparent that the dissociation of 25OHD from the collection of the carriers 
must be highly efficient in order to obtain an accurate total quantitation. The problem is not so 
much for protein-binding assays, radio-immunoassays, high performance liquid chromatography, 
coupled or not to mass spectrometry, that all require an organic extraction step destroying the 
binding capacity of the carriers, but for automated non-extracting sample assays for which 
organic solvents are not compatible, and in which alternative releasing agents with proprietary 
protection are used instead. Since the serum concentration of DBP varies with physiological and 
pathological conditions, such as pregnancy, oestrogen therapy or renal failure [19-21], the 
efficiency of the dissociation and on competition kinetics involved in methods relying on pH 
changes or blocking agents that liberate the 25OHD from its carrier protein could be affected. In 
support of this hypothesis, several reports have highlighted the inaccuracy of total 25OHD 
measurement by automated immunoassays and competitive binding-protein assays performed in 
populations with different levels of DBP [22-25]. Addition of 25OHD3 and 25OHD2 to serum or 
plasma samples is customary in evaluating their recovery in the on-line dissociation step from the 
binding components. The validity of such in vitro recovery experiments is founded on the 
acceptance that exogenous and endogenous vitamin D metabolites fully equilibrate with and bind 
equally to serum components such as binding proteins. In practice, this may not occur. The rise in 
serum pH during storage, decreasing the affinity of binding proteins for Vitamin D metabolites, 
might stimulate the sequestration of exogenous 25-OHD by other serum components, such as 
lipids or lipoproteins. Carter et al. [26] and Horst [27] have reported this artefact showing an 
under-recovery of exogenously added 25OHD in automated assays. This has been extended to 
methods based on HPLC-tandem-mass spectrometry, when Lankes et al. [28] have shown that the 
recovery of 25OHD was affected by suboptimal extraction conditions. These observations, that 
elude complete understanding, question the present process of recovery experiments, and warrant 
caution in interpreting published data. 
The analytical phase 
Supplements currently provide 2 forms of vitamin D: vitamin D3 (cholecalciferol) and vitamin D2 
(ergocalciferol). It is therefore essential that the analytical methods be able to measure the 2 
forms equally in order to avoid an underestimation of the circulating 25(OHD in vitamin D2 
supplemented individuals [29-32]. On the other hand, they must be able to distinguish the 
25(OH)D-C3-epimer and the 24,25(OH)2D, present in different proportions and thus lead to an 
overestimation of circulating 25OHD. This is particularly important for samples from infants 
under the age of 1 year [33] in which the C3-epimer may constitute the major proportion of the 
toal 25OHD. A number of assays have been published and marketed, certain of which claim to 
achieve these goals. The following paragraphs address their characteristics. 
Binding-protein assays and immunoassays 
Table 1a summarizes some of the characteristics of the Binding-protein assays and 
immunoassays. A limited number of protein-binding assays were reported and used clinically 
between 1971 and 1980 (Table 1a). Haddad et al. [34] reported first a manual competitive 
binding-protein assay for the measurement of serum 25OHD. The method was based on the 
displacement of 
3
H-labelled 25OHD3 from post-microsomal kidney supernatants of rachitic rats 
by human serum ether extracts followed by chromatography on silicic acid columns. The authors 
suggested that the crude binding-protein assay recognized equally 25OHD3 and 25OHD2. The 
assay analytical sensitivity was 10 nmol/L. Almost 10 years later, Delvin et al. [35] published a 
simplified protein-binding assay using a -globulin enriched 
fraction (Cohn fraction IV). The serum samples, spiked with purified 
3
H-25OHD3, for recovery 
calculation purposes, were chromatographed on silicic acid columns after lipoprotein 
precipitation with heparin/MnCl2. The analytical sensitivity was 5 nmol/L. Although both 
25OHD3 and 25OHD2 -
globulin fraction did not show affinity for 24,25(OH)2D. These assays requiring chromatographic 
purification on silicic acid and Sephadex LH-20 column after organic extraction were time-
consuming and could not be implemented in routine clinical laboratories. In 1984, Bouillon et al. 
[36] described a non-chromatographic direct assay for 25OHD using rachitic rat serum as the 
source of DBP, after extraction with ethylacetate and cyclohexane. It measured 25OHD3 and 
25OHD2 equally and exhibited a 100% cross-reactivity for 24,25(OH)2D.  Parviainen et al. [37] 
published in 1981, a method based on both HPLC separation of vitamin D metabolites and their 
subsequent measurement by competitive binding-protein for 25OHD and 24,25(OH)2D or 
vitamin D-receptor assay for 1,25(OH)2D. Although the recovery of the labelled metabolites 
was relatively low, the precision was below 10% for 25OHD. This method proved to be time-
consuming and hence was not applied for routine purposes by other groups. Although the above 
assays exhibited clinically acceptable analytical sensitivity and imprecision, they soon became 
obsolete with the development of polyclonal antibodies directed against 25OHD that lead to 
radio-immunoassays (RIAs), and the with the simplification of High-Performance Liquid 
Chromatography (HPLC) equipment that allowed their introduction in clinical laboratories. 
Radioimmunoassays 
RIAs, developed early in the 1980s, constitute the next generation of assay methods. In 1984, 
Bouillon et al. [36] described a simplified non-chromatographic RIA, based on the production of 
rabbit polyclonal antibodies directed against BSA-25OHD3-hemisuccinate conjugate and the 
competition of the serum-extracted 25OHD for [26(27)-methyl-
3
H]-25-hydroxyvitaminD3 as 
tracer. Although the assay was analytically as sensitive as the binding-protein assay, the 2 anti-
sera produced had widely different characteristics in terms of specificity, the cross-reactivity 
varying between 0 and 11% for 25OHD2 and 40 to 270% for 1,25(OH)2D3. The second, 
developed by Hummer et al. [38], required a preliminary chromatography step, and neither 
measured 25OHD2 decreasing its usefulness in assessing total vitamin D nutritional status, in the 
context of where vitamin D2 was widely used as dietary supplement. The next year, Hollis et al. 
[39] described and validated a non-chromatographic radioimmunoassay based on an anti-serum 
raised against the 23,24,25,26,27-pentanor-C-(22)-carboxylic acid vitamin D-BSA conjugate. 
[26,27-methyl-
3
H]-25-hydroxyvitaminD3 was also used as tracer. Although the antibody had little 
affinity for both 1,25(OH)2D3 and 1,25(OH)2D2 (5%) or for vitamin D3 or D2 (10%), it had a 
100% cross-reactivity for 25OHD2 and the other known vitamin D metabolites. Of concern, in 
this assay, is the radically different recovery of labelled 25OHD3 depending whether the tracer 
was added to the sample before or after the addition of acetonitrile. In order to obtain a 
quantitative recovery, the tracer had to be added after the addition of acetonitrile. If it was added 
to the native sample and equilibrated before the extraction step, then the recovery dropped to 
53%. One may therefore question whether the endogenous 25OHD was quantitatively recovered.   
To further confuse matters, in the above-mentioned assays, when recovery was monitored, only 
3
H-25OHD3 was used. Under those conditions, as Stryd et al. [40] had emphasized as soon as 
1978, total 25OHD could be underestimated since the recovery of the 2 vitamin D isomers may 
not necessarily be identical in the extraction processes. 
 Eight years later Hollis et al. [41] described a radioimmunoassay based on goat anti 
23,24,25,26,27-pentanor-C(22)-carboxylic acid of vitamin D-BSA conjugate and 
125
I-vitamin D-
23,24,25,26,27-pentanor-C(22)-carboxylic-amide-3-aminopropyl as the tracer. As in the former 
assay [39] this antibody had little affinity for both 1,25(OH)2D3 and 1a,25(OH)2D2 (2.5%) or for 
vitamin D3 or D2 (<1%), and had a 100% cross-reactivity for 25OHD2 and the other vitamin D 
metabolites. Despite the fact that collectively these metabolites account for a small percentage, 
the assays probably did over-quantify the “true” 25OHD concentration. Nevertheless this RIA 
gave a better estimate of the total vitamin D status as both 25OHD3 and 25OHD2 could be 
quantified equally, on the proviso that 25OHD was quantitatively recovered during the extraction 
procedure. This assay is probably the one that led to the 1
st
 commercial radioimmunoassay for the 
measurement of 25OHD marked by DiaSorin (Stillwater, MN, USA). 
Table 1b summarizes the characteristics of the marketed radioimmunoassays and automated non-
radioactive immunoassays. It can be appreciated that the 2 RIAs differ in their performance 
claimed by the respective manufacturers. The DiaSorin assay measures 25OHD2 and 25OH3 
equally whereas the IDS RIA underestimates 25OHD2 by 25%. The different affinity of the 
antibodies may be due to the difference in the vitamin D analogue used to raise the polyclonal 
antibodies. DiaSorin using as the hapten a vitamin D analogue that lacked the side-chain while 
retaining the open B-ring cis-triene structure common to both vitamins D2 and D3 ensured that the 
antibodies would only recognize this structure. It should be noted that neither assay kit is 
standardised with reference material, thereby diminishing their accuracy. In both cases the lower 
limit of detection is in the range of 3 nmol/L, although there are no independent data to support 
this claim. The assays also differ in their imprecision, DiaSorin reporting an intra-assay CV of 
11.7% at 21.5 nmol/L and IDS a CV of 5.3% at 26 nmol/L. Although DiaSorin and IDS claimed 
100% 25OHD recovery from spiked samples, a 2005 DEQAS survey reported, for the DiaSorin 
assay, a mean recovery of 82% and 83% for exogenous 25OHD3 and 25OHD2 respectively [26]. 
In the case of the IDS RIA kit, the recoveries were 45% and 25% for 25OHD3 and 25OHD2 
respectively. Both methods used an acetonitrile extraction of vitamin D metabolites. Addition of 
NaOH in the initial denaturation-extraction procedure of the IDS RIA has been suggested as the 
source of the difference. This hypothesis can be dismissed as both the DiaSorin and IDS assays 
gave similar results for the specimen containing only endogenous vitamin D. The discrepancy 
can be explained at least in part by the lower affinity of the IDS primary antibody for 25OHD2 
[42]. On the other hand, Glendenning et al. [43] have reported that the DiaSorin RIA 
overestimates total 25OHD within the range of 40-60 nmol/L when compared to a HPLC method.  
Automated Immunoassays 
Radioimmunoassays gradually gave way to automated enzyme-linked immunoassays (EIAs), 
chemiluminescent immunoassays (CLIAs), or competitive binding-protein assays (CBPAs). 
Characteristics of the direct automated methods found in the manufacturers’ information inserts 
are summarised in table 1b. As can been appreciated, according to the manufacturers’ respective 
inserts, 5 out of 6 automated CLIA-based assays methods measured 25OHD2 and 25OHD3 
equivalently (IDS, DiaSorin, Advia Centaur, Vitros, Beckman) whereas the IDS EIA assay 
underestimated 25OHD2 by 25%, the Abbott CLIA by 18% and Roche ECL by 8%. However in 
the case of the Advia Centaur, Le Goff et al. [44] using native clinical samples reported a 30% 
mean overestimation (4–59%) of 25OHD2. These assays exhibited, when reported, variable 
cross-reactivity for 24,25(OH)2D (0% for Beckman to 149% for Roche) and C3-epi-25OHD3 (1% 
for the IDS CLIA assay to 91% for the Roche CBP assay). Interestingly, van den Ouweland et al. 
[45] demonstrated recently, that when present endogenously, C3-epi-25OHD3 is not recognized 
in the Roche CPB assay and warrant caution in interpreting recovery data. All assays have 
satisfactory precision, although defined at variable concentrations. It is interesting to note that 4 
out of 8 automated assays were directly or indirectly standardized against a National Institute of 
Standards and Technology (NIST) Standard Reference Material, however none do provide 
information on recovery of exogenous 25OHD3 or 25OHD2. Automated immunoassays, as well 
as competitive binding protein assays, are based on delicate non-denaturing conditions to free 
25OHD from DBP and other serum binding components to allow its binding either to the kit 
antibodies or DBP. This step, sensitive to matrix effects, may yield varying results [46,47].  
The performance of different commercial assays has recently been reported in independent 
investigations. Su et al. [48] have reported in a comparative study in which serum samples 
contained increasing 25OHD2/25OHD3 ratios that a CBPA exhibited a positive bias when 
samples contained only 25OHD3 and negative biases as the 25OHD2/25OHD3 ratios increased, 
compared to a LC-MS/MS method (10.8%, -23.6%, -38.4%). As the DBP in all likelihood 
recognises the 25OHD isomers equally, the bias could be explained by the inefficient recovery of 
25OHD2. Holmes et al. [49], compared total 25OHD results in 163 clinical specimens obtained 
by 3 direct immunoassays, (DiaSorin Liaison assay, Siemens Centaur, Abbott Architect), to those 
obtained after extraction and followed by LC/MS
2
 and RIA. Their data revealed high degrees of 
random variability and bias relative to LC/MS
2
 and RIA results. Importantly, the magnitude of 
the biases and random errors exceeded the criterion for the total allowable error of a 25OHD test 
[50] in almost ½ of the clinical specimens and led to misclassify an appreciable number of study 
patients as vitamin D deficient. Cavalier et al. [51] also reported a concordance between methods 
varying between 65 to 82% when comparing 6 automated platforms to the NIST/NIH Vitamin D 
Standardization Program (VDSP)-accredited LC/MS
2
 method. As Sempos et al. [52] have 
stressed, this inter-assay variability could lead to misleading conclusions in epidemiological 
studies aiming at evaluating the vitamin D status and to limiting the comparability between 
national surveys. 
High performance Liquid Chromatography 
Table 2 lists the different HPLC methods published the last 35 years. Eisman et al. [53] published 
the 1
st
 HPLC method for the measurement of 25OHD in 1978, followed within a year by 
Gilbertson et al. [54] and Jones [55]. Variants of these initial methods have been published until 
very recently [56-69]. As can be appreciated, although the HPLC-based methods were able to 
separate 25OHD2 from 25OHD3, the authors used either a single in-house or commercial labelled 
25OHD3 internal standard or even surrogate molecules (retinyl acetate, docecanophenone, 
derivatised 25-hydroxydehydrocholesterol, 1-OHD) to monitor the recovery of 25OHD, 
although reporting in most case concentrations for both isomers.  However, Stryd et al. [70], as 
early as 1978, questioned the accepted notion that 25OHD2 and 25OHD3 behaved identically 
during the extraction and chromatographic procedures, and therefore held that using the recovery 
of the tracer 
3
H-25OHD3 to calculate the concentration of the 2 isomers was an error. This led 
them to report values only for 25OHD3 contrary to others. This premise can be extended to the 
proxy tracers. Among variants reported, Shimada et al. [60] used 2 internal standards: 25OHD2 
(IS1) and derivatised 25-hydroxy-7-dehydrocholesterol (IS2) to assess 25OHD3 recovery. 
However the methodology used requires clarification. To start with, they added the 1
st
 internal 
standard after precipitation of plasma proteins with ethanol, thereby removing an important step 
that could lead to misinterpretation. They also performed experiments to evaluate the “absolute” 
recovery of 25OHD3. For this part, they added 25OHD3 standards to 7% buffered Bovine Serum 
Albumin together with the IS1 and performed the extraction. They then added the IS2 after the 
HPLC process they calculated the peak-height ratios between the 25OHD3, the IS1 and IS2. It is 
difficult to conceive how this manoeuvre allows the accurate assessment of the endogenous 
25OHD. Some investigators have proposed a coulometric electrochemical detection system 
[61,69] based on the oxidation potential of the conjugated-diene structure of vitamin D 
metabolites to quantitate 25OHD after the HPLC step. Although this detection method is as 
efficient as methods based on UV, it is not widely adopted by clinical laboratories. This may be 
due to the demanding maintenance of the detectors. The recovery studies vary in their structure 
(labelled or not-labelled tracer, 25OHD or surrogate molecules). Hence it is difficult to assess 
accurately the performance of the methods. Also, precision data vary in terms of the 
concentrations at which the experiments were performed. The accuracy of the methods described 
is ill-defined, as in most cases no calibrator traceable to a standard reference material was 
available. Hymøller et al. [68] have shown that their method yielded results within acceptable 
boundaries for 25OHD2 and 25OHD3 for the National Institute of Standards and Technology 
(NIST) standard reference material 972. 
Mass spectrometry 
Watson et al. [71] described in 1991 an on-line HPLC-Thermospray (TSP) mass spectrometry 
method for vitamin D2, vitamin D3, and their respective mono- and di-hydroxylated metabolites. 
However, at that stage, they reported a superior precision for UV absorbance than for TSP, which 
they attributed to the inherent instability of the TSP ion beam. Since Vogeser [72] and van den 
Ouweland et al. [73] have published extensive reviews on the subject, a summary is presented in 
table 3 that highlights, in a chronological order, the methodology and performance characteristics 
of published methods since 2001 [74-97]. The methods fall into two categories, those involving 
derivatisation of the vitamin D metabolites, and those based on analysis of the native compounds. 
Higashi et al. [74,75], Ding et al. [83] and Kaufmann et al. [97] have developed methods for the 





 following derivatisation by the Diels-Adler reaction with Cookson-like 
reagents.  The addition of a nitrophenyl group to the conjugated-diene portion of the secosteroids, 
increases the ionisation efficiency relative to the native metabolites, and the analytical sensitivity 
by moving molecular masses of the parent ions to a region where there is reduced background 
noise thereby increasing the signal/noise ratio. Although sensitive and specific, these labour-
intensive methods are not transposable for routine analysis in clinical laboratories. They however 
are useful for vitamin D metabolite profiling as shown recently by Kaufmann et al. [97].  
Three candidate reference methods have been proposed in the last 10 years. In 2004, Vogeser et 
al. [76] published the 1
st
 candidate reference method for the measurement of 25OHD3 by stable 
isotope-dilution LC/MS
2
 applicable to clinical laboratory practice. Their method involved a 
protein denaturation process to release the bound vitamin D metabolites, and on-line solid-phase 
extraction before the reverse-phase HPLC coupled to MS
2
 with the detector set in the 
electrospray atmospheric pressure ionisation in the positive mode. In 2010 and 2011, Tai et al. 
[85] and Stepman et al. [86] proposed each a candidate method that differed from that of Voseger 
et al. [75] and from each other in a number of ways. Whereas Voseger et al. [76] utilised a 
25OHD3 internal standard containing 3 Deuterium and 1 
13
C atom, Tai et al. [85] used tri-
deuterated 25OHD3 and 25OHD2, and Stepman et al. [86] hexa-deuterated hydroxylated vitamins 
D2 and D3. Differences lied also in the sample volume (200 l to 2 ml), sample preparation 





and multiple reaction monitoring (MRM) or single reaction monitoring (SRM)]. Despite their 
differences, the IFCC Joint Committee for Traceability in Laboratory Medicine (JCTLM) 
recognized Tai’s et al. [85] and Stepman’s et al. [86] as reference method procedures (RMP). 
Furthermore, the National institute of Standards and technology (NIST) has used Tai’s et al. [85] 
candidate RMP to certify the concentrations of 25(OH)D3 and 25(OH)D2 in their Standard 
Reference Material for Vitamin D in human serum to validate the accuracy for the methods used 
in clinical laboratories. The other tandem-mass spectrometry methods published in the last 10 
years all have quantitation limits below 10 nmol/L well below the concentration considered as 
severe hypovitaminosis (25 nmol/L) [77-82, 84, 87-96].  
The TMS approach has gained ground over the last 10 years, and according to the October 2013 
Vitamin D External Quality Assessment Scheme (DEQAS, www.deqas.org), 25% of the 
participants reported using such a method. Mass spectrometry methods have the advantage of 
being able to measure all species of the 25-hydroxylated vitamin D, including the di-
hydroxylated moieties. Furthermore this physical method is not bound to the conditions imposed 
by the manufacturers, although commercial “turn-key” tandem-mass spectrometry methods are 
now available. Gervasoni et al. [95] have recently reported a comparison between 2 such 
methods. Although both methods are suitable for routine, they make the point that, in their hands, 
the Chromsytems kit does not allow quantitation of 25OHD2 and that the Perkin-Elmer kit 
without derivatisation does not guarantee acceptable performance. 
Problems related to LC-TMS 
The development of refined informatics coupled to the simplified TMS equipment have led users 
to underestimate the complexity of the analytical processes involved in the quantitation of 
vitamin D metabolites and hence to undervalue limitations that may compromise the 
dependability of the data. The sample preparation, including the protein denaturation, the 
extraction, the chromatography, although important, have been overlooked because of the 
preconceived perception that the high selectivity of the mass spectrometer detectors could cover 
for the lack in the preparatory steps. However this misconception has vanished with time when it 
was realised that isobaric compounds co-eluting with the vitamin D metabolites could affect 
precision, accuracy and sensitivity of the method [72,100,101]. Therefore minimal HPLC 
separation of the target metabolites with retention times close to the column dead volume should 
be avoided as it may lead to ion suppression by co-eluting substances [100,101]. 
The example of 1-OHD and 7-OH-4-cholestene-dione (a marker of bile acid mal-absorption) 
as being potential interfering substances in the TMS analysis, but resolved by the HPLC step 
illustrates this point [78]. At the level of the quantification of the two forms of 25OHD, and of 
their respective C3-epimer, the methods described so far make use of the same protonated 
molecular ions [H
+
25OHD3 (m/z 401), H
+
25OHD2 (m/z 413)] but of different transition ions, 
which efficacy of formation is instrument- and energy-dependent [73]. The use of specific 
qualifier and quantifier TMS transition ions, instead of the often-applied water-lost ions, also 
reduces specificity problems [102]. This is exemplified when using 
2
H6-25OHD2 for 25OHD2 
analysis and water loss is monitored. Under these circumstances, HPLC resolution of 25OHD2 
and 25OHD3 is compulsory as the signal contribution from the internal standard to 25OHD3 takes 
place when the water loss from 
2
H6-25OHD2 yields the same transition ion as the 25OHD3 parent 
molecule.  Hence no further selectivity is gained from monitoring a second water loss for the 
daughter ion. [80,82]. Knox et al. [103], recognising that the purification steps are time-
consuming in the perspective of clinical laboratories, proposed a procedure that involves protein 
precipitation with Methanol and a robotised 6-step solid-phase extraction, that could handle up to 
300 samples per day. This procedure should yield cleaner extracts before injection on the HPLC-
TMS instrument, decrease background noise and increase sensitivity. 
As specific as LC-TMS may be for the measurement of vitamin D metabolites, precision and 
accuracy depend on a strict standardisation procedure. This aspect has been Achilles’ heel of this 
field until recently, when SRM was widely made available by the NIST, and weakens the 
threshold definition for vitamin D nutritional status. However there are other elements to the 
inaccuracy of measured 25OHD concentrations. One of these is the C3-epimer of 25OHD3 
present in high concentration in infants’ serum [104] and later, to a lesser extent, in adults [92]. 
This is particularly true for methods that do not separate this metabolite. As there are diverging 
opinions on the biological action of C3-epi-25OHD3 [105,106] the question of reporting its 
concentration remains. Whatever the answer is, it should be quantified for further potential 
clinical evaluation. The observed coefficients of variation in a 2013 DEQAS survey varying 
between 11 to 25% for all tested laboratory methods (437 participants) and between 9.7 to 11.3% 
for TMS-based methods (147 laboratories), illustrate the between laboratory and laboratory 
imprecision. However the lack of a RMP and/or RSM prohibited the evaluation of the accuracy. 
These steps having been solved [85,86], the NIST has produced the SRM 972, consisting of 4 
vials of frozen human serum containing 4 different certified 25(OH)D3 et 25(OH)D2 
concentrations and one of C3-epi-25(OH)D3 [107] and 25(OH)D3 et 25(OH)D2 ethanol 
calibrators [108]. The introduction of these certified reference and calibration materials will 
improve the analytical performance of all methods, as Cavalier et al. [109] have shown for 
automated methods. The precision issue being resolved, accuracy remains. Carter et al. [110] 
have reported in a detailed study of analytical performance of the laboratories using LC-TMS, an 
11% positive bias with respect to the RMP and suggested that it was due to the inclusion of the 
C3-epimer, that most laboratories could not separate from 25OHD3.  
The consortium uniting of the Office of Dietary Supplements of the American National Institutes 
of Health (NIH), the Centre for Disease Control and Prevention (CDC) in Atlanta, the NIST and 
the Ghent University vitamin D Reference Laboratory, has recently initiated a fee-based 3-step 
standardisation program consisting of 1) the calibration and validation of the 25OHD3 et 25OHD2 
concentrations in 40 serum samples measured by LC-TMS in the Ghent laboratory [52]; 2) the 
verification of the efficacy of the calibration by the blind analysis of 10 samples every 3 months; 
and 3) the method comparison and bias estimation according to the Clinical Laboratory 
Standardization Institute (CLSI) guidelines [111]. The laboratory is accredited if the observed 
bias is ± 5,0 % and the imprecision ≤ 10% after 4 cycles (1 year). At the present time only 5 
laboratories have accreditation label [http://ods.od.nih.gov/Research/vdsp.aspx]. 
Conclusions 
The different serum 25OHD values obtained through the years with different methods may have 
lead to misclassification of patients in terms of the vitamin D nutritional status. The historical 
thresholds defining vitamin D sufficiency, insufficiency and deficiency, upon which a 
supplementation decision was taken, are hence to be interpreted cautiously. Cavalier [112] has 
made the point that for assuring the “optimal” serum 25OHD concentration at 75 nmol/L, the 
measured value could vary from 50 to 100 nmol/L and that the threshold should be method-
specific. For example, the Diasorin™ method yielding generally lower values that those obtained 
by LC-TMS, the deficiency and insufficiency thresholds should be re-evaluated. However 
clinicians will slowly adopt this modification. The C3-epi-25OHD3 present in high concentration 
in infants’ serum and to a lesser extent in adults, remains an issue as there are diverging opinions 
on the biological action of C3-epi-1,25(OH)2D3 [113,114]. Whatever the answer is, it should be 
quantified for further potential clinical evaluation. 
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Table 1a: Characteristics for in-house manual competitive binding-protein and radioimmunological 25OHD assays. 
 
























Plasma 1 ml 
















64.1 ± 10.9% 
NR/(10) 
14% at 40 
nmol/L 
NR 
Delvin et al. 
[35] 





















90 ± 1.6% 
NR 
8.9% at 54 
nmol/l 




















107 ± 8.9% 
NR/(2.5) 






















4.5% at 54 
nmol/l 
10.4% at  
32 nmol/L 
Hollis et al. 
[39] 



















Hollis et al. 
[41] 












97 ± 10% 
NR/(7.0) 
5.6% at 23 
nmol/L 







































to a pure preparation 






















standardised by UV 
quantitation 
89-102 at 20 nmol/L 
NR/(3.0) 
5.3% at  
26 nmol/L 
8.2% at  








Immobilised anti-25OHD sheep 
polyclonal Ab, 25OHD-labelled 










5.3% at  
39 nmol/L 
4.6% at  




S 10 l 
2-step procedure  
Denaturation 
DBP + NaOH 
CLIA 
Acridinium-labeled anti-25OHD 







RMP; traceable to the 
NIST SRM 2972 
Recovery not reported 
17.5/(6.0) 

















3.8% at  
20 nmol/L 
12.2% at  








Acridinium-labeled mouse mAb 
Fluorescein vitamin D analog  










RMP; traceable to the 
NIST SRM 2972 
Recovery not reported 
10.5(8.0) 
4.7% at  
34 nmol/L 
11.9% at  
 34 nmol/L 
Architect 1 
Abbott 
S/P 60 l  




Sheep polyclonal Ab-anti-25OHD  
Acridinium-labeled biotinylated 






No mention of 
traceability 
Recovery not reported 
20 (7.8) 
3.1% at  
58 nmol/L 
4.0% at  





S/P 15 l  












in house LC‑ MS/MS 
standardized to the 
NIST standard 
Recovery not reported 
10 (7.5) 




S 60 l 












Recovery not reported 
32 (21.6) 
7.4% at  
56 nmol/L 






S/P 30 l 





25OHD analogue AP-conjugate 







RMP; traceable to the 
NIST SRM 2972 
Recovery not reported 
11 (3.7) 
4.6% at  
39 nmol/L 
8.1% at 
 39 nmol/L 
Unless otherwise specified, the characteristics of the commercial assays are derived from the information given in the respective inserts. 
a
Concentration 
tested not reported. Recovery refers to the % of the exogenously added 25OHD3 (nmol/L) before extraction recovered at completion of the assay. 
RIA:RadioImmnunoAssay; EIA: Enzyme-Linked ImmunoAssay; CLIA: ChemiLuminescent ImmunoAssay, CBPA: Competitive Binding-Protein Assay. 
S: Serum; P: Plasma; LOQ: Lower limit of Quantification defined as a measure with a CV <20%; LOD: Lower limit of Detection defined as the lowest 










pentanor-C(22)-carboxylic-amide-3-aminopropyl; ANSA: 8-anilino-1-naphthalene sulfonic acid; IgG:Immunoglobulin G; mcAB: monoclonal antibody; 
BSA: Bovine Serum Albumin; AP: alkaline phosphatase; Lumi-Phos* 530: Trademark of Lumigen Inc. (Southfield, MI); ID-LC-/MS/MS: isotope dilution-
liquid chromatography/tandem mass spectrometry; RMP: Reference Method Procedure; NIST: National Institute of Standards and Technology; SRM:  
Standard Reference Material. *Personal communication (E Cavalier) 















Eisman et al. 
[51] 
Plasma 4 ml 
Extraction: MeOH:CHCl3 (50:50 v/v) 
Pre-treatment: Sephadex LH-20 
SkellySolve B: CHCl3 (50:50 v/v) 
SkellySolve B: CHCl3 :MeOH (18:2:1 v/v) 
HPLC: Porasil silicic acid column 
2-propanol:Hexane (2.5 :97.5 v/v) 
















al.  [52] 
Serum 1 ml 
Extraction: CHCl2:MeOH (2:1 v/v) 
Pre-treatment: silicic acid 
CH2Cl2:EtOH (98:2 v/v) then n-hexane 
HPLC: Porasil silicic acid column 
EtOH:Hexane (5:95 v/v) 












5.2% at  
28 nml/L 
 





Plasma or serum 2 ml 
Extraction: MeOH:CHCl3 (2:1v/v) 
2-propanol:Hexane (4.5 :95.5 v/v) 
HPLC: Zorbax-SIL 
MeOH:H2O (98.5:1.5 v/v) followed by 
MeOH:H2O (91.0:9.0 v/v) 
Zorbax-ODS 
MeOH:H2O (98.5:1.5 v/v) 

















9.0% at  
30 nmol/L  
 
16% at 
 30 nmol/L  
Dabec  
[54] 
Plasma 0.5 – 3.0 ml 
Pre-treatment: SPE: Sep-pak C18 
MeOH:H2O (69:31 then 80:20 v/v ) 
Silicic acid HPLC 
n-hexane-propane-2-ol (100:2.4 v/v) 




















Plasma 2.0 – 3.0 ml 
Extraction: MeCN 
Pre-treatment: SPE: Sep-pak C18 
MeOH:H2O (70:30 v/v ) then MeCN 
Derivatisation to Isotachysterols 
Zorbax-Sil  
n-hexane-propane-2-ol (95:5 v/v) 












25OHD3: 5.9% at  
57 nmol/L 
25OHD2: 6.8% at  
14 nmol/L 
 
25OHD3: 8.0% at  
62 nmol/L 









 HPLC: Li-Chrosorb-Si 
n-hexane-EtOH (90:10 v/v) 
2
nd
 HPLC: Ultraspher-Octyl C-8 
MeCN:H2O (80:20 v/v) 











 NR NR 
Norris 
[57] 
Plasma/Serum 2.0 ml 
PP:  MeOH 
Pre-treatment: SPE: Sep-pak C18 (MeOH) 
1
st
 HPLC: Li-Chrosorb-Si 
n-hexane-propane-2-ol (91:9 v/v) 
2
nd
 HPLC: Spherisorb-ODS 
MeOH:H2O (88:12 v/v) 












25OHD3: 7.5  
25OHD2: 7.5 
25OHD3: 7.3% at  
28 nmol/L 






Extraction: EtOH/KOH followed by Et2O 
Pre-treatment: Silicic acid column 
n-hexane-propane-2-ol (98.5:1.5 v/v) 
n-hexane-propane-2-ol (84:16 v/v) 
HPLC:J'sphere ODS-HS0 
MeCN:H2O (70:30 v/v) 







55.2 ± 3.3% 
25OHD3:  















HPLC:  Nucleosil 5-C18 column 
MeCN:MeOH (95:5 v/v)/HClO4  


















HPLC: Lichrospher 100 RP-18 
MeCN:MeOH:H2O (90:4:6 v/v) 
Gradient to MeCN:MeOH (40:60 v/v) 








93.0 ± 7.9% 
 
25OHD2: 
81.5 ± 4.7% 
25OHD3: 




25OHD2: 6.1%  
at 15 nmol/L 
25OHD3: 7.7%  
at 22.5 nmol/L 
 
25OHD2: 10.8%  
at 15 nmol/L 
25OHD3: 11.8%  





HPLC: Spherisorb C18, Gradient: 
MeCN:phosphate buffer pH6.5 (20:80 v/v) to 
MeOH :MeCN :THF (65:20:15 v/v) 









at 17.5 nmol/L 
 
25OHD3: 2% 






HPLC: Ultrabase C18  column 
Gradient from MeOH:H20 (90:10 v/v) to 
MeOH:propane-2-ol  (90:10 v/v) 













Serum 1 ml 
PP (MeCN) 
Extraction:  
HPLC:  SB-CN column 
MeOH :H2O  (67:33 v/v) 









101.2 ± 9.4% 
(8 – 253 nmol/L) 
 
25OHD3:  
95.1 ± 7.6% 
(11 – 260 nmol/L) 
25OHD2: 12.5 
25OHD3: 12.5 
25OHD2: 13% at 
11.0 nmol/L 





1 ml Serum 
PP: EtOH 
Extraction: n-hexane:MeCl2 
HPLC: Spheri-5-ODS column 
Gradient from MeCN:MeOH (85:15 v/v) to 
MeCN:MeCl2:MeOH (70:20:10 v/v/v) 







 and 25OHD2) 
25OHD: >85% 











Extraction: SPE Discovery DSC-18 
MeOH:H2O (2:3 v/v), MeOH. 
HPLC: Purospher STAR-RP-18e  








25OHD3: 96.9 ± 





25OHD3: 5.3% at 
57 nmol/L 
 




1.5 ml Plasma 
Saponification: MeOH/KOH/ASC 
Extraction: heptane 
HPLC: YMC-C30 RP column 
Gradient: H2O:EtOH (95:5 v/v), H2O:EtOH 
(60:40 v/v); H2O:EtOH (10:90 v/v) 







at 75 nmol/L 
25OHD3: 100.3% 











500 l Serum 
PP: MeOH:propane-2-ol (80:20 v/v) 
Extraction : n-hexane 










25OHD2: 72% at 
24 nmol/L 




25OHD3: 6.2% at 
27.5 nmol/L 
 
PP: Protein Precipitation; SPE: Solid Phase Extraction; LLE: Liquid-Liquid Extraction; OLTFE: On line turboflow extraction; ECD: 
Electrochemical Detection; CEAD: Coulometric Electrode Array Detector. 
25OHdC: 25-Hydroxy-7-dehydrocholesterol; 1-OHD3 : 1-alpha-hydroxyvitamin D3; MBPTD: 4-[4-(6-methoxy-2-benzoxazolyl)phenyl]-1,2,4-
triazoline-3,5-dione; 
MeNH2: Methyl Amine; MeOH: Methanol; EtOH: Ethanol; NH4Ac: Ammonium acetate; MeCN: Acetonitrile: Et2O: diethyl-ether; KOH: 
Potassium hydroxide; MeCl2: Dichloromethane; HClO4: Perchloric acid; THF: Tetrahydrofuran; ASC: 20% Ascorbic acid water solution;  
IS: Internal Standard; NR: Not reported; #: Spiked samples with 25 nmol/L of each of the 2 metabolites; †: % recovery ± SD for the 2 deuterated 
compounds at a 50 f  ††:  Expressed as percent recovery of the NIST-certified values;  
 






















Plasma 20 l 
PP: MeCN  
Extraction: LLE (AcOEt) 
Derivatisation (DMEQ-TAD) 
HPLC: J’sphere ODS H-80 












98.8 – 109.8% 
(12.5 nmol/L)  
 
25OHD2:  







at 21.9 nmol/L 
25OHD2: 3.17% 





Plasma 20 l 
PP: MeCN  
Extraction: LLE (AcOEt) 
Derivatisation (NPTAD) 
HPLC: J’sphere ODS H-80 



















Serum 200 l 
NaOH, PP: MeCN  





 100 RP-18 









405 > 159  
 
25OHD3:  
401 > 159 
25OHD3:  
91 ± 1.6% 










Serum 100 l 
PP: MeOH  
Extraction: SPE: Bond-Elute C18
® 
HPLC: CapCell PAK C-18 UG120
®
 








407 > 263 
 
25OHD3: 
401 > 257  
25OHD2:  















at 50 nmol/L 
25OHD2: 4.5% 
at 7.5 nmol/L 
25OHD3: 2.5% 
at 47.5 nmol/L 
25OHD2: 5.1% 





Serum 100 l 
PP: MeOH:Propanol (80:20 v/v) 
Extraction: LLE: n-Hexane 
HPLC: BDS C8
®
 ThermoHypersil  




In-house IS:  
2
H6-25OHD3:  
407.2 > 389.4 
 
25OHD3:  
401.8 > 383.5 
25OHD2: 
413.5 > 395.4 
25OHD3: 91 – 110 %  
at 128 - 256 nmol/L 
 
25OHD2: 94 - 108% 
at 158 - 317 nmol/L 
 
25OHD3: < 4.0 












 Chen 20008 
[77] 
Serum 200 l 
PP: MeCN 
Extraction: SPE: Oasis HLB
®
  












407.7 > 389.7 
 
25OHD3: 
401.4 > 383.4 
25OHD2: 
413.4 > 395.4 
25OHD3: 99 ± 2 %  
at 34.2 – 132.8 nmol/L 
 
25OHD2: 95 ± 0.8% 




















 Bunch 2009 
[78] 
Serum 100 l 
PP: MeOH  
Extraction: OLTFE 
HPLC: Hypersil Gold aQ
®
 




In-house IS  
2
H6-25OHD3:  
407.2 > 389.4 
 
25OHD2: 
413.5 > 395.4 
25OHD3:  











Serum 100 l 
PP: MeCN  
Extraction: automated LLE: 96-well 
Commercial IS  
2
H6-25OHD3:  








25OHD3: 9.4%  
at 32 nmol/L 
25OHD2: 8.6% 














401.4 > 365.2 
25OHD2: 



















389 > 371 
2
H6-25OHD2 
401 > 383 
 
25OHD3:  
395 > 377 
25OHD2: 
413.5 > 395.4 
108 – 113%  
Expressed as total 25OHD 
added 




25OHD: 5.7% at 
17 nmol/L  
 
25OHD: 8.7% 




Serum 200 l 
PP: MeCN 





HPLC: ACQUITY BEH C18
®
 









613 > 298 
2
H6-25OHD2 
625 > 298 
 
25OHD3:  
607 > 298 
25OHD2: 
619 > 298 
2
H6-25OHD3:  
84.9 ± 2.4%† 
2
H6-25OHD2:  






at 0.025 nmol/L 
 #25OHD2: 







Serum 250 l 




H2O-MeOH/H2O (60/40 v/v)-MeOH 
HPLC: ACQUITY UPLC BEH C18
®
 
0.1% CHO2H /2 mM NH4Ac; 







407.5 > 159.2 
 
25OHD3:  
401.5 > 159.2 
25OHD2: 
413.4 > 83.1 
25OHD3:  
94.9-106.9%  
at 49.9 – 99.9 nmol/L 
25OHD2: 
82.7-100.3% 









at 64.9 nmol/L 
25OHD2: 4.2% 
at 33.3 
  nmol/L 
 
25OHD3: 6.0% 
at 64.9 nmol/L 
25OHD2: 3.8% 
at 33.3 nmol/L 




pH adjusted to 9.8 (Na2CO3) 
LLE Extraction: n-hexane/EtAc (50/50 
v/v) 
Residue dissolved in MeOH 
HPLC: Zorbax CB-CN column 







404 > 386 
2
H3-25OHD2 




401 > 383 
25OHD2 
C3-epi-25OHD2: 
413 > 395 
Stds traceable to 
NIST  
25OHD3:  
100.0 – 10% 
25OHD2: 

















Serum 250 l 
 Extraction: LLE: NaOH/n-hexane 
Sephadex LH-20 chromatography  
MeOH/CHCl3/cC6H14 (1/4/8, v/v/v) 
2-dimensional UPLC Chromatography 
1:Acquity BEH 300 C4
®
 column 







MeOH/H2O/ CHO2H (50/50/0.025) 







407.3 > 159.3 
2
H6-25OHD2 
419.4 > 159.4 
 
25OHD3:  
401.3 > 159.3 
25OHD2: 
413.4 > 159.4 
C3-epi-25OHD3 
401.3 > 159.3 
Stds Traceable to 
NIST 
25OHD3:  
71% ± 4%†† 
25OHD2: 
70% ± 8%†† 
 
25OHD3:  
1.12  ± 0.05  
25OHD2:  
1.22 ± 0.05  
 
25OHD3: 1.4% 
at 30.8 nmol/L 
 25OHD2: 2.0% 
at 64.1 nmol/L 
 
25OHD3: 1.7% 
at 30.8 nmol/L 
 25OHD2: 1.1% 




Serum 100 l 




Gradient: H2O/MeOH+1% toluene 





407.3 > 263.3 
2
H6-25OHD2 





25OHD3: 2.0  
25OHD2: 2.0  
 
25OHD3: 3.7% 
at 5 nmol/L 
25OHD2: 16.7% 
at 5.0 nmol/L 
 
25OHD3: 15.4% 
at 5.0 nmol/L 
401.2 > 257.2 
25OHD2: 
413.3 > 337.2 
Stds traceable to 
NIST  
25OHD2: 14.0% 











MeCN/H2O+0.1% CHO2H gradient 







564 > 298 
 
25OHD3:  
558 > 298 
 
25OHD3:  








at 25 nmol/L 
 
25OHD3: 7.0% 





Serum 100 l 
PP: MeOH/MeCN/0.05 M ZnSO4 
(6.5/1/2 v/v/v) 
HPLC: Kinetex C18  
NH4CHO2H/MeOH Gradient 








389 > 371 




401 > 209 
 
25OHD3:  
383 > 365 
383 > 211 
25OHD2: 
395 > 209 
395 > 269 






25OHD2: 1.5  
 
25OHD3: 1.5 
25OHD2: 0.5  
 
25OHD3: 3% at 
41.7 nmol/L 
 











MeOH/H2O (5/95 v/v) 
HPLC: Kinetex
®
 PFP column 







407.3 > 263.2 
407.3 > 159.2 
 
25OHD3:  













at 39.8 nmol/L 
25OHD2: 4.9% 
at 27.5 nmol/L 
C3-epi25OHD3: 
4.2% at 20.1 
nmol/L 
 401.3 > 159.2 
 
25OHD2: 
413.4 > 159.2 
C3-epi25OHD3 
401.3 > 257.2 
401.3 > 159.2 
NIST SRM 2972 





at 39.8 nmol/L 
25OHD2: 3.4% 
at 27.5 nmol/L 
C3-epi25OHD3: 
3.4% at 20.1 
nmol/L 
 Farrell 2012 
[89] 
Serum 150 l 
PP: 2.0 M ZnSO4/MeOH 
TMS: 0.2M/MeOH 
SPE:Oasis ElutionHLB plate 
MeOH/H2O (60/40 v/v) 
2 mM NH4Ac + 0.1% CHO2H / 
MeOH/2 mM NH4Ac + 0.1% CHO2H 
(27/73 v/v) 
UPLC: ACQUITY BEH C8
®
 
2 mM NH4Ac + 0.1% CHO2H / 
MeOH/2 mM NH4Ac + 0.1% CHO2H 







407.3 > 159.1 
2
H3-25OHD2 
416.3 > 398.3 
 
25OHD3:  
401.3 > 383.5 
401.3 > 159.1 
25OHD2:  
413.3 > 83.1 











at 79 nmol/L 
 
25OHD: 2.0% 





Serum 300 l 
PP: MeCN/2 mM ZnSO4  
(87/13 v/v)/MeOH 
Extraction: SPE Strata C18E
®
 
MeCN/H2O (45/55 v/v) 
Acetone/MeCN (20/80 v/v) 
HPLC: Zorbax cyanopropyl column 







383.3 > 211.1 
25OHD2:  
395.3 > 209.1 
C3-epi25OHD3 
383.3 > 211.1 
 






On-line SPE: X-Terra C18 









at 59.8 nmol/L 
25OHD2: 1.8% 
MeOH/0.1% CHO2H + 2mM NH4Ac in 
H2O (98/2 v/v)/ 0.1% CHO2H + 2mM 
NH4Ac in H2O (68/32 v/v) 
HPLC: Sunfire C18 
MeOH/0.1% CHO2H + 2mM NH4Ac in 
H2O (98/2 v/v)/ 0.1% CHO2H + 2mM 







419.4 > 355.2 
 
25OHD3:  
401.4 > 365.3 
25OHD2:  
413.4 > 355.3 
at 99.5 nmol/L 
 
25OHD3: 5.9% 
at 66.7 nmol/L 
25OHD2: 5.9% 





Extraction: 1M NaOH/n-heptane 
HPLC: XTerra MS C8 + Restek 
columns 













419.4 > 355.2 
 
25OHD3:  
401.3 > 355.3 
25OHD2:  
413.4 > 355.3 
Stds traceable to 
NIST 
25OHD3: 80 - 116% 
(23.4 nmol/L)  






at 58 nmol/L 
25OHD2: 2.8% 
at 85 nmol/L 
 
25OHD3: 9.6% 
at 63 nmol/L 
25OHD2: 6.2% 




Serum or plasma 25l 
PP: MeCN 
2-dimension HPLC:  
SPE: Turboflow XL C18-P
®
 column 
Step gradient 0.1% CHO2H; 
MeCN/propanol-2ol/acetone (44/40/20 












389.3 > 263.2 
 
25OHD3:  
383.3 > 365.2 
25OHD2:  
395.3 > 377.4 
Stds traceable to 
NIST 
25OHD3: 102.6 – 106% 
(36.9 – 59.8 nmol/L)  
25OHD2: NR 
25OHD3: 2.2 





at 18 nmol/L 
25OHD2: 10.6% 
at 18 nmol/L 
 
25OHD3: 7.2% 
at 18 nmol/L 
25OHD2: NR 





Extraction: n-heptane  
HPLC: Zorbax SB-C18 
Step Gradient:  









416.3 > 358.2 
 
25OHD3: ≥ 62% 
(125 - 200 nmol/L) 
25OHD2: ≥ 72% 
(18 - 200 nmol/L) 
25OHD3: 6.2 
 25OHD2: 6.2 
 
25OHD3: NR 
25OHD2: NR  
25OHD3: 2.2% 
at 18 nmol/L 
25OHD2: 2.1% 
at 18 nmol/L 
 
25OHD3: 4.4% 





401.3 > 365.2 
25OHD2: 
413.3  > 355.2 
at 18 nmol/L 
25OHD2: 5.0 




Serum 100 l 
PP: 0.1M HCl/0.2M ZnSO4/MeOH 
Extraction: n-hexane/t-butyl ether (1/1 
v/v) 
Derivatisation (DMEQ-TAD)/ AcOEt 









613 > 298 
2
H3-25OHD2 
625 > 298 
 
25OHD3:  
746.6 > 468 
25OHD2: 












at 55 nmol/L 
 25OHD2: 3-4%  
at 83 nmol/L 
 
25OHD3: 4-7% 
at 55 nmol/L 
 25OHD2: 4-7%  
at 83 nmol/L 
HPLC: High Performance Liquid Chromatography; UPLC: UlLC: Performance Liquid Chromatography; MS: Mass Spectrometry; TMS: Tandem-
Mass Spectrometry; AP: Atmospheric Pressure; ESI: Electron Spray Ionisation; APCI: Atmospheric Pressure Chemical Ionisation; APPI: 
Atmospheric Pressure Photo-Ionisation; ID: Isotope Dilution; MRM: Multiple Reaction Monitoring; SRM: Selected Reaction Monitoring; PP: 
Protein Precipitation; SPE: Solid Phase Extraction; LLE: Liquid/Liquid Extraction; OLTFE: On-line turboflow extraction;  
DMEQ-TAD: 4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalyl)ethyl]-1,2,4-triazoline-3,5-dione; NPTAD: 4-(4-Nitrophenyl)-1,2,4-
triazoline-3,5-dione; PTAD: 4-phenyl-1,2,4-triazoline-3,5-dione; EAD: enzyme-assisted derivatisation; GP: Girard Reagent P reagent (1-
(carboxymethyl)pyridinium chloride hydrazide); 25OHdC: 25-Hydroxy-7-dehydrocholesterol; 1-OHD3 : 1-alpha-hydroxyvitamin D3 
AcOEt: Ethyl acetate; MeNH2: Methyl Amine; MeOH: Methanol; EtOH: Ethanol; NH4Ac: Ammonium acetate; MeCN: Acetonitrile: Et2O: 
diethyl-ether; KOH: Potassium hydroxide; MeCl2: Dichloromethane; HClO4: Perchloric acid; THF: Tetrahydrofuran; ASC: 20% Ascorbic acid 
water solution; CHO2H: Formic acid; 
IS: Internal Standard; NR: Not reported; NIST: National Institute of Standards and Technology (Gaithersburg, USA); SRM: Standard Reference 
Material; Levels 1-4: level 1: human serum; level 2: human serum diluted with horse serum to achieve a lower 25(OH)Dx concentration; level 3: 
human serum fortified with 25(OH)D2; and level 4: human serum fortified with 3-epi-25(OH)D3;  
*Recovery: Exogenously added vitamin D metabolite; †: % recovery ± SD for the 2 deuterated compounds at a 50 f  ††:  
Expressed as % recovery of the NIST-certified values;  
 
Figure 1. Relationship between doses of vitamin D3 supplementation and net changes in serum 
25OHD concentrations in RCTs by assay type. 
 
Legends: Each empty circle represents one study. The area of the circle is proportional to the 
inverse of the within-study variances. The larger the bubble is, the larger the sample size and the 
smaller the standard error of the changes in 25OHD. Reprinted with permission from Vitamin D 
and Calcium: A Systematic Review of Health Outcomes (Update) Newberry et al. 2014 [8] 
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